Tag Archives | SABCS

Everolimus plus exemestane is the biggest advance in breast cancer since Herceptin

2011 European Multidisciplinary Cancer Congress Breast cancer news¬† There were two noteworthy breast trials with new data at the 2011 ESMO ECCO oncology congress in Stockholm this past weekend: 1) The phase III BOLERO-2 study for everolimus (Afinitor) plus exemestane is according to Sally Church, “probably the biggest single advance in breast since the Herceptin […]

Continue Reading

Conference Coverage: the week in review

Now that summer is officially over, the fall pharma/biotech conference season has started. You can find out details of the conferences Icarus Consultants will be attending by checking out our conference schedule. If you are interested in our meeting coverage services or a conference report, please contact us. This week, we followed two conferences remotely […]

Continue Reading

Potential New Triple Negative Breast Cancer Biomarkers

Sally Church on Pharma Strategy Blog has written about recent research in triple-negative breast cancer (TNBC). She discusses a published study from Vanderbilt that identified six different subtypes of the disease; each subtype being sensitive to different drug therapies. As Sally points out these subtypes could be used as a potential biomarker for patient selection […]

Continue Reading